Structural and functional in silico analysis of LRRK2 missense substitutions

Molecular Biology Reports

Volumn 41, Issue 4, 2014, Pages 2529-2542

  Cardona, Fernando ^a,b   Tormos Pérez, Marta ^a,c,d   Pérez Tur, Jordi ^a,b  

^a INSTITUTO DE BIOMEDICINA DE VALENCIA   (Spain)

^b CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED SOBRE ENFERMEDADES NEURODEGENERATIVAS CIBERNED   (Spain)

^c UNIVERSITAT POLITÈCNICA DE VALÈNCIA   (Spain)

^d UNIVERSITY OF SALAMANCA   (Spain)

Author keywords

Function; Kinase; LRRK2; Parkinson s disease; Stability; Structure

Indexed keywords

LEUCINE RICH REPEAT KINASE 2; LRRK2 PROTEIN, HUMAN; PROTEIN SERINE THREONINE KINASE;

ARTICLE; COMPUTER ANALYSIS; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME ANALYSIS; ENZYME PHOSPHORYLATION; ENZYME STABILITY; ENZYME STRUCTURE; GENETIC POLYMORPHISM; LRRK2 GENE; MISSENSE MUTATION; MUTATIONAL ANALYSIS; PARKINSON DISEASE; PROTEIN DOMAIN; PROTEIN TERTIARY STRUCTURE; AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; CHEMICAL STRUCTURE; CHEMISTRY; GENETICS; HUMAN; METABOLISM; MOLECULAR DYNAMICS; MOLECULAR GENETICS; PROTEIN STABILITY; STRUCTURE ACTIVITY RELATION;

ARMADILLO;

AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; HUMANS; MODELS, MOLECULAR; MOLECULAR DYNAMICS SIMULATION; MOLECULAR SEQUENCE DATA; MUTATION, MISSENSE; PARKINSON DISEASE; PROTEIN INTERACTION DOMAINS AND MOTIFS; PROTEIN STABILITY; PROTEIN STRUCTURE, TERTIARY; PROTEIN-SERINE-THREONINE KINASES; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84897545390     PISSN: 03014851     EISSN: 15734978     Source Type: Journal    
DOI: 10.1007/s11033-014-3111-z     Document Type: Article

References (54)

1. Seol W (2010) Biochemical and molecular features of LRRK2 and its pathophysiological roles in Parkinson's disease. BMB Rep 43(4):233-244
2. Paisan-Ruiz C, Jain S, Evans EW, Gilks WP, Simon J, van der Brug M, Lopez de Munain A, Aparicio S, Gil AM, Khan N, Johnson J, Martinez JR, Nicholl D, Carrera IM, Pena AS, de Silva R, Lees A, Marti-Masso JF, Perez-Tur J, Wood NW, Singleton AB (2004) Cloning of the gene containing mutations that cause PARK8-linked Parkinson's disease. Neuron 44(4):595-600 (Pubitemid 39531224)
3. Huang Y, Cheung L, Rowe D, Halliday G (2004) Genetic contributions to Parkinson's disease. Brain Res Brain Res Rev 46(1):44-70 (Pubitemid 39030771)
4. Santpere G, Ferrer I (2009) LRRK2 and neurodegeneration. Acta Neuropathol 117(3):227-246
5. Mata IF, Wedemeyer WJ, Farrer MJ, Taylor JP, Gallo KA (2006) LRRK2 in Parkinson's disease: protein domains and functional insights. Trends Neurosci 29(5):286-293
6. Marin I (2008) Ancient origin of the Parkinson disease gene LRRK2. J Mol Evol 67(1):41-50
7. Kornev AP, Haste NM, Taylor SS, Eyck LF (2006) Surface comparison of active and inactive protein kinases identifies a conserved activation mechanism. Proc Natl Acad Sci USA 103(47):17783-17788 (Pubitemid 44852237)
8. Greggio E, Zambrano I, Kaganovich A, Beilina A, Taymans JM, Daniels V, Lewis P, Jain S, Ding J, Syed A, Thomas KJ, Baekelandt V, Cookson MR (2008) The Parkinson disease-associated leucine-rich repeat kinase 2 (LRRK2) is a dimer that undergoes intramolecular autophosphorylation. J Biol Chem 283(24):16906-16914
9. Klein CL, Rovelli G, Springer W, Schall C, Gasser T, Kahle PJ (2009) Homo- and heterodimerization of ROCO kinases: LRRK2 kinase inhibition by the LRRK2 ROCO fragment. J Neurochem 111(3):703-715
10. Gotthardt K, Weyand M, Kortholt A, Van Haastert PJ, Wittinghofer A (2008) Structure of the Roc-COR domain tandem of C. tepidum, a prokaryotic homologue of the human LRRK2 Parkinson kinase. EMBO J 27(16):2239-2249
11. Deng J, Lewis PA, Greggio E, Sluch E, Beilina A, Cookson MR (2008) Structure of the ROC domain from the Parkinson's disease-associated leucine-rich repeat kinase 2 reveals a dimeric GTPase. Proc Natl Acad Sci USA 105(5):1499-1504 (Pubitemid 351346543)
12. Lesage S, Brice A (2009) Parkinson's disease: from monogenic forms to genetic susceptibility factors. Hum Mol Genet 18(R1):R48-R59
13. Luzon-Toro B, Rubio de la Torre E, Delgado A, Perez-Tur J, Hilfiker S (2007) Mechanistic insight into the dominant mode of the Parkinson's disease-associated G2019S LRRK2 mutation. Hum Mol Genet 16(17):2031-2039 (Pubitemid 47354886)
14. Jaleel M, Nichols RJ, Deak M, Campbell DG, Gillardon F, Knebel A, Alessi DR (2007) LRRK2 phosphorylates moesin at threonine-558: characterization of how Parkinson's disease mutants affect kinase activity. Biochem J 405(2):307-317 (Pubitemid 47075166)
15. West AB, Moore DJ, Biskup S, Bugayenko A, Smith WW, Ross CA, Dawson VL, Dawson TM (2005) Parkinson's disease-associated mutations in leucine-rich repeat kinase 2 augment kinase activity. Proc Natl Acad Sci USA 102(46):16842-16847 (Pubitemid 41688864)
16. Webber PJ, West AB (2009) LRRK2 in Parkinson's disease: function in cells and neurodegeneration. FEBS J 276(22):6436-6444
17. Kuntal BK, Aparoy P, Reddanna P (2010) EasyModeller: A graphical interface to MODELLER. BMC Res Notes 3:226
18. Cardona F, Sanchez-Mut JV, Dopazo H, Perez-Tur J (2011) Phylogenetic and in silico structural analysis of the Parkinson disease-related kinase PINK1. Hum Mutat 32(4):369-378
19. Capriotti E, Fariselli P, Casadio R (2005) I-Mutant2.0: predicting stability changes upon mutation from the protein sequence or structure. Nucleic Acids Res 33((Web Server issue)):W306-W310 (Pubitemid 44529932)
20. Cheng J, Randall A, Baldi P (2006) Prediction of protein stability changes for single-site mutations using support vector machines. Proteins 62(4):1125-1132 (Pubitemid 43364175)
21. Yin S, Ding F, Dokholyan NV (2007) Eris: An automated estimator of protein stability. Nat Methods 4(6):466-467. doi: 10.1038/nmeth0607-466 (Pubitemid 46852064)
22. Teng S, Srivastava AK, Wang L (2010) Sequence feature-based prediction of protein stability changes upon amino acid substitutions. BMC Genomics 11(Suppl 2):S5
23. Majewski J, Ott J (2003) Amino acid substitutions in the human genome: evolutionary implications of single nucleotide polymorphisms. Gene 305(2):167-173 (Pubitemid 36259767)
24. Kumar P, Henikoff S, Ng PC (2009) Predicting the effects of coding non-synonymous variants on protein function using the SIFT algorithm. Nat Protoc 4(7):1073-1081
25. Ramensky V, Bork P, Sunyaev S (2002) Human non-synonymous SNPs: server and survey. Nucleic Acids Res 30(17):3894-3900 (Pubitemid 35012462)
26. Ferrer-Costa C, Gelpi JL, Zamakola L, Parraga I, de la Cruz X, Orozco M (2005) PMUT: A web-based tool for the annotation of pathological mutations on proteins. Bioinformatics 21(14):3176-3178 (Pubitemid 41418475)
27. Capriotti E, Calabrese R, Casadio R (2006) Predicting the insurgence of human genetic diseases associated to single point protein mutations with support vector machines and evolutionary information. Bioinformatics 22(22):2729-2734 (Pubitemid 44742391)
28. Zhao Z, Wang Z, Gu Y, Feil R, Hofmann F, Ma L (2009) Regulate axon branching by the cyclic GMP pathway via inhibition of glycogen synthase kinase 3 in dorsal root ganglion sensory neurons. J Neurosci 29(5):1350-1360
29. Lesage S, Condroyer C, Lannuzel A, Lohmann E, Troiano A, Tison F, Damier P, Thobois S, Ouvrard-Hernandez AM, Rivaud-Pechoux S, Brefel-Courbon C, Destee A, Tranchant C, Romana M, Leclere L, Durr A, Brice A (2009) Molecular analyses of the LRRK2 gene in European and North African autosomal dominant Parkinson's disease. J Med Genet 46(7):458-464
30. Mills RD, Mulhern TD, Cheng HC, Culvenor JG (2012) Analysis of LRRK2 accessory repeat domains: prediction of repeat length, number and sites of Parkinson's disease mutations. Biochem Soc Trans 40(5):1086-1089
31. Vancraenenbroeck R, Lobbestael E, Weeks SD, Strelkov SV, Baekelandt V, Taymans JM, De Maeyer M (2012) Expression, purification and preliminary biochemical and structural characterization of the leucine rich repeat namesake domain of leucine rich repeat kinase 2. Biochim Biophys Acta 1824(3):450-460
32. Neubert M, Ridder DA, Bargiotas P, Akira S, Schwaninger M (2011) Acute inhibition of TAK1 protects against neuronal death in cerebral ischemia. Cell Death Differ 18(9):1521-1530
33. Garrido JJ, Simon D, Varea O, Wandosell F (2007) GSK3 alpha and GSK3 beta are necessary for axon formation. FEBS Lett 581(8):1579-1586 (Pubitemid 46528923)
34. Nichols WC, Elsaesser VE, Pankratz N, Pauciulo MW, Marek DK, Halter CA, Rudolph A, Shults CW, Foroud T (2007) LRRK2 mutation analysis in Parkinson disease families with evidence of linkage to PARK8. Neurology 69(18):1737-1744 (Pubitemid 350059302)
35. Lorenzo-Betancor O, Samaranch L, Ezquerra M, Tolosa E, Lorenzo E, Irigoyen J, Gaig C, Pastor MA, Soto-Ortolaza AI, Ross OA, Rodriguez-Oroz MC, Valldeoriola F, Marti MJ, Luquin MR, Perez-Tur J, Burguera JA, Obeso JA, Pastor P (2012) LRRK2 haplotype-sharing analysis in Parkinson's disease reveals a novel p. S1761R mutation. Mov Disord 27(1):146-151
36. Gilsbach BK, Ho FY, Vetter IR, van Haastert PJ, Wittinghofer A, Kortholt A (2012) Roco kinase structures give insights into the mechanism of Parkinson disease-related leucine-rich-repeat kinase 2 mutations. Proc Natl Acad Sci USA 109(26):10322-10327
37. Gloeckner CJ, Kinkl N, Schumacher A, Braun RJ, O'Neill E, Meitinger T, Kolch W, Prokisch H, Ueffing M (2006) The Parkinson disease causing LRRK2 mutation I2020T is associated with increased kinase activity. Hum Mol Genet 15(2):223-232 (Pubitemid 43125977)
38. Nichols RJ, Dzamko N, Morrice NA, Campbell DG, Deak M, Ordureau A, Macartney T, Tong Y, Shen J, Prescott AR, Alessi DR (2010) 14-3-3 binding to LRRK2 is disrupted by multiple Parkinson's disease-associated mutations and regulates cytoplasmic localization. Biochem J 430(3):393-404
39. Reichling LJ, Riddle SM (2009) Leucine-rich repeat kinase 2 mutants I2020T and G2019S exhibit altered kinase inhibitor sensitivity. Biochem Biophys Res Commun 384(2):255-258
40. Li X, Moore DJ, Xiong Y, Dawson TM, Dawson VL (2010) Reevaluation of phosphorylation sites in the Parkinson disease-associated leucine-rich repeat kinase 2. J Biol Chem 285(38):29569-29576
41. Mata IF, Wilhoite GJ, Yearout D, Bacon JA, Cornejo-Olivas M, Mazzetti P, Marca V, Ortega O, Acosta O, Cosentino C, Torres L, Medina AC, Perez-Pastene C, Diaz-Grez F, Vilarino-Guell C, Venegas P, Miranda M, Trujillo-Godoy O, Layson L, Avello R, Dieguez E, Raggio V, Micheli F, Perandones C, Alvarez V, Segura-Aguilar J, Farrer MJ, Zabetian CP, Ross OA (2011) Lrrk2 p. Q1111H substitution and Parkinson's disease in Latin America. Parkinsonism Relat Disord 17(8):629-631
42. Zach S, Felk S, Gillardon F (2010) Signal transduction protein array analysis links LRRK2 to Ste20 kinases and PKC zeta that modulate neuronal plasticity. PLoS ONE 5(10):e13191
43. Nolen B, Taylor S, Ghosh G (2004) Regulation of protein kinases; controlling activity through activation segment conformation. Mol Cell 15(5):661-675 (Pubitemid 39194898)
44. Anand VS, Reichling LJ, Lipinski K, Stochaj W, Duan W, Kelleher K, Pungaliya P, Brown EL, Reinhart PH, Somberg R, Hirst WD, Riddle SM, Braithwaite SP (2009) Investigation of leucine-rich repeat kinase 2: enzymological properties and novel assays. FEBS J 276(2):466-478
45. Koprivica V, Cho KS, Park JB, Yiu G, Atwal J, Gore B, Kim JA, Lin E, Tessier-Lavigne M, Chen DF, He Z (2005) EGFR activation mediates inhibition of axon regeneration by myelin and chondroitin sulfate proteoglycans. Science 310(5745):106-110 (Pubitemid 41434546)
46. Mosse YP, Laudenslager M, Longo L, Cole KA, Wood A, Attiyeh EF, Laquaglia MJ, Sennett R, Lynch JE, Perri P, Laureys G, Speleman F, Kim C, Hou C, Hakonarson H, Torkamani A, Schork NJ, Brodeur GM, Tonini GP, Rappaport E, Devoto M, Maris JM (2008) Identification of ALK as a major familial neuroblastoma predisposition gene. Nature 455(7215):930-935
47. Fiore R, Puschel AW (2003) The function of semaphorins during nervous system development. Front Biosci 8:s484-s499
48. Yuan Z, Becker EB, Merlo P, Yamada T, DiBacco S, Konishi Y, Schaefer EM, Bonni A (2008) Activation of FOXO1 by Cdk1 in cycling cells and postmitotic neurons. Science 319(5870):1665-1668 (Pubitemid 351432504)
49. Kelly PA, Rahmani Z (2005) DYRK1A enhances the mitogen-activated protein kinase cascade in PC12 cells by forming a complex with Ras, B-Raf, and MEK1. Mol Biol Cell 16(8):3562-3573 (Pubitemid 41077070)
50. Kim EJ, Sung JY, Lee HJ, Rhim H, Hasegawa M, Iwatsubo T, Min do S, Kim J, Paik SR, Chung KC (2006) Dyrk1A phosphorylates alpha-synuclein and enhances intracellular inclusion formation. J Biol Chem 281(44):33250-33257 (Pubitemid 46036707)
51. Kamikawaji S, Ito G, Iwatsubo T (2009) Identification of the autophosphorylation sites of LRRK2. Biochemistry 48(46):10963-10975
52. Liu M, Kang S, Ray S, Jackson J, Zaitsev AD, Gerber SA, Cuny GD, Glicksman MA (2011) Kinetic, mechanistic, and structural modeling studies of truncated wild-Type leucine-rich repeat kinase 2 and the G2019S mutant. Biochemistry 50(43):9399-9408
53. Liu M, Bender SA, Cuny GD, Sherman W, Glicksman M, Ray SS (2013) Type II kinase inhibitors show an unexpected inhibition mode against parkinson's disease-linked LRRK2 mutant G2019S. Biochemistry 52(10):1725-1736
54. Kumari U, Tan EK (2009) LRRK2 in Parkinson's disease: genetic and clinical studies from patients. FEBS J 276(22):6455-6463